Genomic determinants of hepatitis C virus antiviral therapy outcomes: Toward individualized treatment

Annals of Hepatology

Volumn 11, Issue 6, 2012, Pages 827-837

  Venegas, Mauricio ^a   Brahm, Javier ^a   Villanueva, Rodrigo A ^b  

^a HOSPITAL CLÍNICO UNIVERSIDAD DE CHILE   (Chile)

^b UNIVERSIDAD ANDRÉS BELLO   (Chile)

Author keywords

Direct acting antiviral; Genetic variant; IL28B polymorphisms; Peginterferon ribavirin treatment (PegiFNalpha RBV)

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; BOCEPREVIR; DANOPREVIR; FILIBUVIR; IDX 184; INOSINE TRIPHOSPHATASE; INTERFERON; INTERLEUKIN 28B; LOW DENSITY LIPOPROTEIN RECEPTOR; MERICITABINE; NALNAPREVIR; PEGINTERFERON; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PHOSPHATASE; PROTEINASE INHIBITOR; RIBAVIRIN; SETROBUVIR; SIMEPREVIR; SOFOSBUVIR; TEGOBUVIR; TELAPREVIR; UNCLASSIFIED DRUG; VANIPREVIR;

ANTIVIRAL ACTIVITY; BONE MARROW TOXICITY; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; GENE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOMICS; GENOTYPE; HEMOLYSIS; HEMOLYTIC ANEMIA; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IL28B GENE; IMMUNE RESPONSE; NONHUMAN; PERSONALIZED MEDICINE; RACE DIFFERENCE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SOUTH AND CENTRAL AMERICA; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS GENOME;

EID: 84869424619     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)31407-3     Document Type: Review

References (84)

1. Global burden of hepatitis C working group. Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol 2004; 44: 20-9.
2. Simmonds P, Bukh J, Combet C, Deléage G, Enomoto N, Feinstone S, Halfon P, et al. Consensus proposals for a uni-fied system of nomenclature of hepatitis C virus genoty-pes. Hepatology 2005; 42: 962-73.
3. Gómez J, Martell M, Quer J, Cabot B, Esteban JI. Hepatitis C viral quasispecies. J Viral Hepat 1999; 6: 3-16.
4. Bowden DS, Berzsenyi MD. Chronic hepatitis C virus infec-tion: genotyping and its clinical role. Future Microbiol 2006; 1: 103-12.
5. Cristina J. Genetic diversity and evolution of hepatitis C virus in the Latin American region. J Clin Virol 2005; 34(Suppl. 2): S1-S7.
6. Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005; 436: 967-72.
7. Adinolfi LE, Utili R, Andreana A, Tripodi MF, Rosario P, Mor-mone G, Ragone E, et al. Relationship between genotypes of hepatitis C virus and histopathological manifestations in chronic hepatitis C patients. Eur J Gastroenterol Hepa-tol 2000; 12: 299-304.
8. Hoofnagle JH. Course and outcome of hepatitis C. Hepato-logy 2002; 36: S21-S29.
9. Tellinghuisen TL, Evans MJ, von Hahn T, You S, Rice CM. Studying hepatitis C virus: making the best of a bad virus. J Virol 2007; 81: 8853-67.
10. Poenisch M, Bartenschlager R. New insights into structure and replication of the hepatitis C virus and clinical impli-cations. Semin Liver Dis 2010; 30: 333-47.
11. Gouttenoire J, Penin F, Moradpour D. Hepatitis C virus nonstructural protein 4B: a journey into unexplored terri-tory. Rev Med Virol 2010; 20: 117-29.
12. Vermehren J, Sarrazin C. New HCV therapies on the hori-zon. Clin Microbiol Infect 2011; 17: 122-34.
13. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, La-yden TJ, Perelson AS. Hepatitis C. viral dynamics in vivo and the antiviral efficacy of interferon-α therapy. Science 1998; 282: 103-7.
14. NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statements 2002; 19: 1-46.
15. Randall RE, Goodbourn S. Interferons and viruses: an in-terplay between induction, signalling, antiviral responses and virus countermeasures. J Gen Virol 2008; 89: 1-47.
16. Reichard O, Andersson J, Schvarcz R, Weiland O. Ribavirin treatment for chronic hepatitis C. Lancet 1991; 337: 1058-61.
17. Bodenheimer HC Jr, Lindsay KL, Davis GL, Lewis JH, Thung SN, Seeff LB. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. He-patology 1997; 26: 473-7.
18. Tanabe Y, Sakamoto N, Enomoto N, Kurosaki M, Ueda E, Maekawa S, Yamashiro T, et al. Synergistic inhibition of in-tracellular hepatitis C virus replication by combination of ribavirin and interferon-alpha. J Infect Dis 2004; 189: 1129-39.
19. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, Shiffman ML, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1493-9.
20. Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, Schiff ER, et al. Hepatitis Interventional Thera-py Group. A randomized, double-blind trial comparing pe-gylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34: 395-403.
21. Parker WB. Metabolism and antiviral activity of ribavirin. Virus Res 2005; 107: 165-71.
22. Leyssen P, De Clercq E, Neyts J. The anti-yellow fever vi-rus activity of ribavirin is independent of error-prone re-plication. Mol Pharmacol 2006; 69: 1461-7.
23. Rodriguez-Torres M, Jeffers LJ, Sheikh MY, Rossaro L, Ankoma-Sey V, Hamzeh FM, Martin P; Latino Study Group. Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C. N Engl J Med 2009; 360: 257-67.
24. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, Bochud M, et al. Genetic variation in IL28B is associa-ted with chronic hepatitis C and treatment failure: a ge-nome-wide association study. Gastroenterology 2010; 138: 1338-45.
25. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, Kidd J, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801.
26. Montes-Cano MA, García-Lozano JR, Abad-Molina C, Rome-ro-Gómez M, Barroso N, Aguilar-Reina J, et al. Interleukin-28B genetic variants and hepatitis virus infection by different genotypes. Hepatology 2010; 52: 33-7.
27. Tillmann HL, Thompson AJ, Patel K, Wiese M, Tenckhoff H, Nischalke HD, Lokhnygina Y, et al. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology 2010; 139: 1586-92.
28. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
29. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-9.
30. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and riba-virin therapy. Nat Genet 2009; 41: 1100-4.
31. McCarthy JJ, Li JH, Thompson A, Suchindran S, Lao XQ, Patel K, Tillmann HL, et al. Replicated association between an IL28B gene variant and a sustained response to pegyla-ted interferon and ribavirin. Gastroenterology 2010; 138: 2307-14.
32. Venegas M, Villanueva RA, González K, Brahm J. IL28B po-lymorphisms associated with therapy response in Chilean chronic hepatitis C patients. World J Gastroenterol 2011; 17: 3636-9.
33. Cavalcante LN, Abe-Sandes K, Angelo AL, Machado TM, Le-maire DC, Mendes CM, Pinho JR, et al. IL28B polymorphis-ms are markers of therapy response and are influenced by genetic ancestry in chronic hepatitis C patients from an admixed population. Liver Int 2012; 32: 476-86.
34. Ridruejo E, Solano A, Marciano S, Galdame O, Adrover R, Cocozzella D, Delettieres D, et al. Genetic variation in in-terleukin-28B predicts SVR in hepatitis C genotype 1 Ar-gentine patients treated with PEG IFN and ribavirin. Ann Hepatol 2011; 10: 452-7.
35. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsme-yer S, Whitmore TE, Kuestner R, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003; 4: 63-8.
36. Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK, Langer JA, et al. IFN-lambdas mediate antivi-ral protection through a distinct class II cytokine recep-tor complex. Nat Immunol 2003; 4: 69-77.
37. Li M, Liu X, Zhou Y, Su SB. Interferon-lambdas: the modula-tors of antivirus, antitumor, and immune responses. J Leu-koc Biol 2009; 86: 23-32.
38. Kelly C, Klenerman P, Barnes E. Interferon lambdas: the next cytokine storm. Gut 2011; 60: 1284-93.
39. Witte K, Witte E, Sabat R, Wolk K. IL-28A, IL-28B, and IL29: promising cytokines with type I interferon-like pro-perties. Cytokine Growth Factor Rev 2010; 21: 237-51.
40. Fox BA, Sheppard PO, O'Hara PJ. The role of genomic data in the discovery, annotation and evolutionary interpreta-tion of the interferon-lambda family. PLoS One 2009; 4: e4933.
41. Ank N, West H, Paludan SR. IFN-lambda: novel antiviral cytokines. J Interferon Cytokine Res 2006; 26: 373-9.
42. Marcello T, Grakoui A, Barba-Spaeth G, Machlin ES, Ko-tenko SV, MacDonald MR, et al. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gas-troenterology 2006; 131: 1887-98.
43. Robek MD, Boyd BS, Chisari FV. Lambda interferon inhibits hepatitis B and C virus replication. J Virol 2005; 79: 3851-54.
44. Pagliaccetti NE, Eduardo R, Kleinstein SH, Mu XJ, Bandi P, Robek MD. Interleukin-29 functions cooperatively with in-terferon to induce antiviral gene expression and inhibit hepatitis C virus replication. J Biol Chem 2008; 283: 30079-89.
45. Muir AJ, Shiffman ML, Zaman A, Yoffe B, de la Torre A, Flamm S, et al. Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chro-nic genotype 1 hepatitis C virus infection. Hepatology 2010; 52: 822-32.
46. Urban TJ, Thompson AJ, Bradrick SS, Fellay J, Schuppan D, Cronin KD, et al. IL28B genotype is associated with diffe-rential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 2010; 52: 1888-96.
47. Honda M, Sakai A, Yamashita T, Nakamoto Y, Mizukoshi E, Sakai Y, et al. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 2010; 139: 499-509.
48. Fukuhara T, Taketomi A, Motomura T, Okano S, Ninomiya A, Abe T, Uchiyama H, et al. Variants in IL28B in liver reci-pients and donors correlate with response to peg-interfe-ron and ribavirin therapy for recurrent hepatitis C. Gastroenterology 2010; 139: 1577-85.
49. Abe H, Hayes N, Ochi H, Maekawa T, Tsuge M, Miki D, et al. IL28B variation affects expression of interferon stimu-lated genes and effect of PEG-interferon and ribavirin therapy. J Hepatol 2011; 54: 1094-101.
50. Chen L, Borozan I, Feld J, Sun J, Tannis LL, Coltescu C, et al. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 2005; 128: 1437-44.
51. Feld JJ, Nanda S, Huang Y, Chen W, Cam M, Pusek SN, et al. Hepatic gene expression during treatment with PEGin-terferon and ribavirin: identifying molecular pathways for treatment response. Hepatology 2007; 46: 1548-63.
52. Sarasin-Filipowicz M, Oakeley EJ, Duong FH, Christen V, Terracciano L, Filipowicz W, et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci USA 2008; 105: 7034-9.
53. Dill MT, Duong FH, Vogt JE, Bibert S, Bochud PY, Terrac-ciano L, et al. Interferon-induced gene expression is a stronger predictor of treatment response than IL28B ge-notype in patients with hepatitis C. Gastroenterology 2011; 140: 1021-31.
54. Ahlenstiel G, Booth DR, George J. IL28B in hepatitis C vi-rus infection: translating pharmacogenomics into clinical practice. J Gastroenterol 2010; 45: 903-10.
55. Rauch A, Rohrbach J, Bochud PY. The recent breakthroughs in the understanding of host genomics in hepatitis C. Eur J Clin Invest 2010; 40: 950-9.
56. Thio CL, Thomas DL. Interleukin-28b: a key piece of the hepatitis C virus recovery puzzle. Gastroenterology 2010; 138: 1240-3.
57. Mordstein M, Michiels T, Staeheli P. What have we learned from the IL28 receptor knockout mouse? J Interferon Cytokine Res 2010; 30: 579-84.
58. Jensen DM, Pol S. IL28B genetic polymorphism testing in the era of direct acting antivirals therapy for chro-nic hepatitis C: ten years too late? Liver Int 2012; 32(Suppl. 1): 74-8.
59. Rice CM. New insights into HCV replication: potential anti-viral targets. Top Antivir Med 2011; 19: 117-20.
60. Poordad F, Bronowicki J-P, Gordon SC, et al. IL28B poly-morphism predicts virologic response in patients with he-patitis C genotype 1 treated with boceprevir (BOC) combination therapy. J Hepatol 2011; 54(Suppl. 1): 6.
61. Soriano V, Poveda E, Vispo E, Labarga P, Rallón N, Barreiro P. Pharmacogenetics of hepatitis C. J Antimicrob Chemo-ther 2012; 67: 523-9.
62. McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacob-son IM, Afdhal NH, Heathcote EJ, et al. Telaprevir for pre-viously treated chronic HCV infection. N Engl J Med 2010; 362: 1292-303.
63. Jacobson I, Catlett I, Marcellin P, et al. Telaprevir substantially improved SVR rates across all IL28B geno-types in the ADVANCE trial. J Hepatol 2011; 54(Suppl. 1): 542-3.
64. Akuta N, Suzuki F, Hirakawa M, et al. Amino acid substitu-tion in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to te-laprevir with peginterferon and ribavirin. Hepatology 2010; 52: 421-9.
65. Schaefer EA, Chung RT. Anti-hepatitis C virus drugs in de-velopment. Gastroenterology 2012; 142: 1340-50.e1.
66. Pol S, Aerssens J, Zeuzem S, et al. Similar SVR rates in IL28B CC, CT or TT prior relapser partial-or null-respon-der patients treated with telaprevir/peginterferon/riba-virin: retrospective analysis of the REALIZE study. J Hepatol 2011; 54(Suppl. 1): 6-7.
67. De Franceschi L, Fattovich G, Turrini F, Ayi K, Brugnara C, Manzato F, Noventa F, et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. He-patology 2000; 31: 997-1004.
68. Fellay J, Thompson AJ, Ge D, Gumbs CE, Urban TJ, Shianna KV, Little LD, et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature 2010; 464: 405-8.
69. Sumi S, Marinaki AM, Arenas M, Fairbanks L, Shobowale-Bakre M, Rees DC, Thein SL, et al. Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency. Hum Ge-net 2002; 111: 360-7.
70. Dubuisson J, Helle F, Cocquerel L. Early steps of the hepa-titis C virus life cycle. Cell Microbiol 2008; 10: 821-7.
71. Hennig BJ, Hellier S, Frodsham AJ, Zhang L, Klenerman P, Knapp S, Wright M, et al. Association of low-density lipo-protein receptor polymorphisms and outcome of hepatitis C infection. Genes Immun 2002; 3: 359-67.
72. Pineda JA, Caruz A, Di Lello FA, Camacho A, Mesa P, Neu-kam K, Rivero-Juárez A, et al. Low-density lipoprotein re-ceptor genotyping enhances the predictive value of IL28B genotype in HIV/hepatitis C virus-coinfected patients. AIDS 2011; 25: 1415-20.
73. Pineda JA, Caruz A, Rivero A, Neukam K, Salas I, Camacho A, Palomares JC, et al. Prediction of response to pegyla-ted interferon plus ribavirin by IL28B gene variation in pa-tients coinfected with HIV and hepatitis C virus. Clin Infect Dis 2010; 51: 788-95.
74. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Izumi N, et al. Comparison of full-length se-quences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J Clin Invest 1995; 96: 224-30.
75. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Ogura Y, et al. Mutations in the nonstructu-ral protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996; 334: 77-81.
76. Kurosaki M, Enomoto N, Murakami T, Sakuma I, Asahina Y, Yamamoto C, Ikeda T, et al. Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of he-patitis C virus in relation to the response to interferon-beta therapy. Hepatology 1997; 25: 750-3.
77. Shirakawa H, Matsumoto A, Joshita S, Komatsu M, Tanaka N, Umemura T, Ichijo T, et al. Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host fac-tors. Hepatology 2008; 48: 1753-60.
78. Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Someya T, Kobayashi M, et al. Association of amino acid substitu-tion pattern in core protein of hepatitis C virus genotype1b high viral load and non-virological response to interfe-ron-ribavirin combination therapy. Intervirology 2005; 48: 372-80.
79. Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzu-ki Y, Hosaka T, et al. Prediction of response to pegylated interferon and ribavirin in hepatitis C by polymorphisms in the viral core protein and very early dynamics of viremia. Intervirology 2007; 50: 361-8.
80. Okanoue T, Itoh Y, Hashimoto H, Yasui K, Minami M, Take-hara T, Tanaka E, et al. Predictive values of amino acid se-quences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study. J Gas-troenterol 2009; 44: 952-63.
81. Hayashi K, Katano Y, Honda T, Ishigami M, Itoh A, Hirooka Y, Ishikawa T, et al. Association of interleukin 28B and mu-tations in the core and NS5A region of hepatitis C virus with response to peg-interferon and ribavirin therapy. Li-ver Int 2011; 31: 1359-65.
82. Kurosaki M, Tanaka Y, Nishida N, Sakamoto N, Enomoto N, Honda M, Sugiyama M, et al. Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chro-nic hepatitis C using genetic polymorphism in IL28B and vi-ral factors. J Hepatol 2011; 54: 439-48.
83. Hayes CN, Kobayashi M, Akuta N, Suzuki F, Kumada H, Abe H, Miki D, et al. HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy. Gut 2011; 60: 261-7.
84. Hiraga N, Abe H, Imamura M, Tsuge M, Takahashi S, Hayes CN, Ochi H, et al. Impact of viral amino acid substitutions and host interleukin-28b polymorphism on replication and susceptibility to interferon of hepatitis C virus. Hepatolo-gy 2011; 54: 764-71.